New Advances in the Treatment of Onychomycosis

Abstract

At present, treating mycosis of the nail apparatus still remains a challenge. The infectious focus is entrapped on a specific anatomic structure where permanent resolution is sometimes unattainable, which means that onychomycosis often becomes a chronic condition that persists in an active state in the range of several years. The priority in recent developments of onychomycosis’ pharmacotherapy lies on topical monotherapies for use in patients who cannot take oral medication or prefer a topical drug and, as an additional advantage, to combine them with oral drugs and/or medical devices to expand the current treatment possibilities. This review encompasses therapeutic options for onychomycosis in the status quo. Two novel topical drugs, efinaconazole and tavaborole, received approval from the competent regulatory agency, the Food and Drug Administration (FDA), in 2014.